Metal-based photosensitizers for photodynamic therapy: the future of multimodal oncology?. (June 2020)

• Record Type: Journal Article
• Authors: McFarland, Sherri A.; Mandel, Arkady; Dumoulin-White, Roger; Gasser, Gilles
• Is Part Of: Current opinion in chemical biology. Volume 56(2020)
• Page Start: 23
• Page End: 27
• Publication Date: 2020-06
• Subjects: Bioinorganic chemistry -- Medicinal inorganic chemistry -- Metals in medicine -- Photodynamic therapy -- Photosensitizer; Bioorganic chemistry -- Periodicals; Biology -- Periodicals; Biochemistry -- Periodicals; Clinical biochemistry -- Periodicals; Biochemistry -- Periodicals; Chimie bio-organique -- Périodiques; Biologie -- Périodiques; 572.05
• DOI: 10.1016/j.cbpa.2019.10.004
• Languages: English
• ISSNs: 1367-5931

Abstract

Abstract: Photodynamic therapy (PDT) is an approved medical technique to treat certain forms of cancer. It has been used to complement traditional anticancer modalities such as surgery, chemotherapy or radiotherapy, and in certain cases, to replace these treatments. One critical parameter of PDT is the photosensitizer (PS); historically, a purely organic macrocyclic tetrapyrrole-based structure. This short review surveys two recent clinical examples of metal complexes, namely TOOKAD®-Soluble and TLD-1433, which have ideal photophysical properties to act as PDT PSs. We highlight the important role played by the metal ions in the PS for PDT activity.